Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Einstein Researchers Develop Novel Drug That Regenerates Erectile Nerves Damaged by Prostate Surgery
April 19, 2021—(BRONX, NY)—Researchers atAlbert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer. The drug was tested in rats, and the findings were published online today inJCI Insight. (Source: Einstein News)
Source: Einstein News - April 19, 2021 Category: Universities & Medical Training Source Type: news

Gene drug could help erection nerves regrow after prostate cancer surgery, rat study finds
Research by the Albert Einstein College of Medicine in New York found that blocking a gene that slows down nerve recovery could restore rats' erectile function within weeks of nerve damage. (Source: the Mail online | Health)
Source: the Mail online | Health - April 19, 2021 Category: Consumer Health News Source Type: news

New treatment for ED after prostate surgery being developed, researchers say
Men undergoing surgery for prostate cancer may no longer have to live with erectile dysfunction afterward, thanks to an innovative new treatment, researchers said in a paper published Monday by JCI Insight. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 19, 2021 Category: Consumer Health News Source Type: news

Prostate cancer: The sexual symptom warning you may be at risk of a tumour developing
PROSTATE cancer is the most common cancer in men in the UK, with around 40,000 men diagnosed with prostate cancer every year in England alone. Symptoms can take years to surface but if battling with this sexual symptom it could determine your risk. (Source: Daily Express - Health)
Source: Daily Express - Health - April 19, 2021 Category: Consumer Health News Source Type: news

Hope for men with advanced prostate cancer after Australian treatment trials
Australian doctors are claiming positive results after trials using a new combination of drugs have seen the quality of life improve for... (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2021 Category: Consumer Health News Source Type: news

Can You Ever Be Cured of Prostate Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 16, 2021 Category: General Medicine Source Type: news

How Quickly Does Prostate Cancer Spread?
Title: How Quickly Does Prostate Cancer Spread?Category: Diseases and ConditionsCreated: 4/16/2021 12:00:00 AMLast Editorial Review: 4/16/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 16, 2021 Category: Cancer & Oncology Source Type: news

Healthy Lifestyle May Offset Genetic Risk in Prostate Cancer Healthy Lifestyle May Offset Genetic Risk in Prostate Cancer
Adhering to a healthy lifestyle may offset the heightened risk of lethal prostate cancer in patients with adverse genetic risk factors, according to results of a large US study presented at AACR 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study: New approach may boost prostate cancer immunotherapies
(Cedars-Sinai Medical Center) Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body's immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news

Cancer symptoms: Erectile dysfunction may be due to an ‘advanced’ tumour in the prostate
CANCEROUS tumours might spread from the prostate gland to other body parts; this is known as "advanced" prostate cancer, which may lead to erectile dysfunction as one of the symptoms of the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - April 14, 2021 Category: Consumer Health News Source Type: news

AACR: Healthy Lifestyle May Counter High Genetic Risk for Lethal Prostate Cancer
But adherence to healthy lifestyle not associated with decreased risk for overall prostate cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 12, 2021 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pathology, Urology, Conference News, Source Type: news

AACR: Healthy Lifestyle May Counter High Genetic Risk for Lethal Prostate Cancer
MONDAY, April 12, 2021 -- Genetic factors are associated with an increased risk for overall and lethal prostate cancer, and adherence to a healthy lifestyle can reduce the risk for lethal disease among men in the highest genetic risk quartile,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2021 Category: Pharmaceuticals Source Type: news

Healthy Living Helps Ward Off Deadly Prostate Cancers in Men at High Risk
MONDAY, April 12, 2021 -- A nutritious diet, regular exercise and other components of a healthy lifestyle may reduce the odds of lethal prostate cancer in men with a high genetic risk for it, researchers report. " The excess genetic risk of lethal... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 12, 2021 Category: General Medicine Source Type: news

Healthy Living Helps Ward Off Deadly Prostate Cancers in Men at High Risk
Title: Healthy Living Helps Ward Off Deadly Prostate Cancers in Men at High RiskCategory: Health NewsCreated: 4/12/2021 12:00:00 AMLast Editorial Review: 4/12/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 12, 2021 Category: Cancer & Oncology Source Type: news

Better treatment for aggressive prostate cancer
(University of Colorado Anschutz Medical Campus) Published this week in the journal Molecular Cancer Research, Cramer's study specifically looks at how the loss of two specific prostate tumor-suppressing genes -- MAP3K7 and CHD1 --increases androgen receptor signaling and makes the patient more resistant to the anti-androgen therapy that is typically administered to reduce testosterone levels in prostate cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: news

Prostate cancer: Eight changes to bathroom habits indicating you may be at risk
PROSTATE cancer is the most common cancer among men in the UK. Your body will go through changes in the initial stages of the disease with particular changes to your toilet habits. Any of these eight unusual bathroom habits could indicate your risk. (Source: Daily Express - Health)
Source: Daily Express - Health - April 11, 2021 Category: Consumer Health News Source Type: news

iTheranostics, Novartis ink FAP-targeted drug development agreement
Sofie subsidiary iTheranostics has inked an agreement with Novartis to collaborat...Read more on AuntMinnie.comRelated Reading: Novartis touts phase III prostate cancer study results SNMMI celebrates 60th anniversary with special issue Jubilant inks deal to invest $25M in Sofie Novartis to buy Endocyte for $2.1B SNMMI: Theranostic agent awarded Image of the Year (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 9, 2021 Category: Radiology Source Type: news

Prostate cancer: Eight changes to bathroom habits indicating you may be at risk of disease
PROSTATE cancer is the most common cancer among men in the UK. Your body will go through changes in the initial stages of the disease with particular changes to your toilet habits. Any of these eight unusual bathroom habits could indicate your risk. (Source: Daily Express - Health)
Source: Daily Express - Health - April 9, 2021 Category: Consumer Health News Source Type: news

Men with low health literacy less likely to choose active surveillance for prostate cancer after tumor profiling
(University of Illinois at Chicago) A new study shows that in a predominantly Black, urban patient population with substantial social disadvantage, tumor profiling decreased patient acceptance of active surveillance. Men with low health literacy were more than seven times less likely to accept active surveillance if their tumors were profiled. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2021 Category: Cancer & Oncology Source Type: news

Sen. Thom Tillis says he has had surgery for prostate cancer
Republican Sen. Thom Tillis of North Carolina says he has undergone surgery for prostate cancer (Source: ABC News: Health)
Source: ABC News: Health - April 8, 2021 Category: Consumer Health News Tags: Health Source Type: news

Prostate Cancer: Symptoms, Tests, and Treatments
Prostate cancer is the most common cancer among men and the second most common cause of cancer-related deaths among American men. Learn more about the disease ’s symptoms, tests, and treatments. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 6, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Radiomics AI algorithm differentiates sclerotic bone lesions
A radiomics-based machine-learning model can differentiate bone islands an...Read more on AuntMinnie.comRelated Reading: MRI radiomics can predict risk of breast cancer recurrence CCTA radiomics yields insights into nature of coronary artery disease AI, radiomics predicts prostate cancer recurrence Radiomics, AI can guide NSCLC treatment decisions CT radiomics classifies small nodules found in CT lung screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 1, 2021 Category: Radiology Source Type: news

SNMMI provides update on COVID-19 vaccine and PET/CT
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has updated it...Read more on AuntMinnie.comRelated Reading: SNMMI issues new guidelines on V/Q scans FDG-PET/CT shows COVID-19 vaccine uptake PET/CT guidance offers valuable approach to lung biopsies SNMMI 2020: PSMA-PET/CT changes prostate cancer management SNMMI 2020: How nuclear medicine handled COVID-19 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 31, 2021 Category: Radiology Source Type: news

MIT's Koch Institute gets new director
Five months after its founding director, Tyler Jacks, stepped down from the position, MIT's Koch Institute for Integrative Cancer Research has a new director in Matthew Vander Heiden, an MIT biology professor and researcher of cancer cell metabolism. Vander Heiden has been a member of the Koch Institute since 2010 and as an associate director since 2017. He also works as a medical oncologist at the Dana-Farber Cancer Institute, treating prostate cancer patients, a position he intends to keep, per… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 31, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

MIT's Koch Institute gets new director
Five months after its founding director, Tyler Jacks, stepped down from the position, MIT's Koch Institute for Integrative Cancer Research has a new director in Matthew Vander Heiden, an MIT biology professor and researcher of cancer cell metabolism. Vander Heiden has been a member of the Koch Institute since 2010 and as an associate director since 2017. He also works as a medical oncologist at the Dana-Farber Cancer Institute, treating prostate cancer patients, a position he intends to keep, per… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 31, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

What Foods Kill Prostate Cancer?
Title: What Foods Kill Prostate Cancer?Category: Diseases and ConditionsCreated: 3/31/2021 12:00:00 AMLast Editorial Review: 3/31/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 31, 2021 Category: Cancer & Oncology Source Type: news

Fitness, Fundraising and Friendship for Prostate Cancer
By Syed Neaz Ahmad FRSALONDON, Mar 30 2021 (IPS-Partners) Over the Pandemic months, most activities – social, cultural, economic & philanthropic have been hit hard. The worst-hit has been patients suffering from serious diseases. Most have shied away from visiting their doctors and referral fell by 52,000 due to Covid-19. However, as they say, life goes on, and in this case, death goes on too. Prostate Cancer UK – a charity exclusive to the disease – report that despite awareness and development in technology – every 45 minutes a man dies of this dreaded disease. It is the ‘most commonly ...
Source: IPS Inter Press Service - Health - March 30, 2021 Category: International Medicine & Public Health Authors: Syed Neaz Ahmad FRSA Tags: Health Source Type: news

Sen. Thom Tillis says he'll have surgery for prostate cancer
Sen. Thom Tillis says he's got prostate cancer and will undergo surgery next week in North Carolina to treat it (Source: ABC News: Health)
Source: ABC News: Health - March 29, 2021 Category: Consumer Health News Tags: Health Source Type: news

CTC mutations may predict outcomes in some castrate-resistant prostate cancer patients
(American Association for Cancer Research) Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 26, 2021 Category: Cancer & Oncology Source Type: news

ENDO: In Utero 17 - OHPC Exposure Ups Later Cancer Risk
Risk for any cancer increased in adult offspring with in utero exposure, particularly colorectal, prostate cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 24, 2021 Category: Cancer & Oncology Tags: Endocrinology, Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Oncology, Pharmacy, Urology, Conference News, Source Type: news

Decades of radiation-based scientific theory disproven by Ben-Gurion University US-based study
(American Associates, Ben-Gurion University of the Negev) According to the study, lower levels of several types of cancers were found when the radiation levels were on the higher end of the spectrum rather than on the lower end. Among both men and women, there was a significant decrease in lung, pancreatic, colon and rectal cancers. Among men, there were additional decreases in brain and bladder cancers. There was no decrease in cervix, breast or prostate cancers or leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 24, 2021 Category: International Medicine & Public Health Source Type: news

Novartis touts phase III prostate cancer study results
Novartis is highlighting results from a phase III study that has investigate...Read more on AuntMinnie.comRelated Reading: Preclinical lung imaging offers effective evaluation of drug candidates Small study supports radiation before CAR-T therapy Firm nabs $1.4M for prostate cancer drug Ga-68 DOTATATE PET/MRI could be boon for meningioma Novartis to buy Endocyte for $2.1B (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 23, 2021 Category: Radiology Source Type: news

Drug used during pregnancy may increase cancer risk in mother's adult children
(The Endocrine Society) Exposure in the womb to a drug used to prevent miscarriage appears to raise the offspring's cancer risk decades later, especially for colorectal and prostate cancers, researchers have found. They will present the results of their new study Tuesday at ENDO 2021, the Endocrine Society's annual meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 23, 2021 Category: Cancer & Oncology Source Type: news

Novel radiotracer shows promise for prostate imaging
An experimental new radiotracer is effective when used with PET/CT for detectin...Read more on AuntMinnie.comRelated Reading: Blue Earth touts fluciclovine F-18 research at ASCO GU Blue Earth eyes new uses for fluciclovine F-18 Blue Earth buys therapeutic rights to rhPSMA technology Use F-18 fluciclovine PET/MRI to stage prostate cancer PET with Axumin boosts prostate cancer outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 22, 2021 Category: Radiology Source Type: news

Having a single personal doctor may sometimes lead to unnecessary tests
(Frontiers) Having a single personal physician may promote overtesting for the PSA biomarker for prostate cancer, suggests new study from the University of Florida (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 22, 2021 Category: International Medicine & Public Health Source Type: news

Study could help develop biosensors for non-invasive diagnosis of diseases
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Brazilian researchers tested the capacity of different materials to produce sensors for the detection of PCA3, a gene that is overexpressed in prostate cancer. The technique can also be used to diagnose infectious diseases, including COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 22, 2021 Category: Infectious Diseases Source Type: news

Prostate cancer uses metabolic switch to thrive after hormone therapy
(Duke University Medical Center) Studying the cellular metabolism of prostate cancer, a team of Duke Health-led researchers identified a key reason hormone therapies eventually fail, while also laying out a way to bypass the problem using an entirely new therapeutic approach. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 22, 2021 Category: Cancer & Oncology Source Type: news

White button mushrooms could slow progression of prostate cancer
(The Endocrine Society) The chemicals present in white button mushrooms may slow the progression of prostate cancer, according to a mouse study presented virtually at ENDO 2021, the Endocrine Society's annual meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 20, 2021 Category: Cancer & Oncology Source Type: news

When will PET/MRI live up to its promise?
From its early days 10 years ago to the present, PET/MRI has developed fro...Read more on AuntMinnie.comRelated Reading: FDG-PET/MRI offers option for pediatric Hodgkin lymphoma PET/MRI, CT predict pancreatic cancer treatment response Use F-18 fluciclovine PET/MRI to stage prostate cancer PET/MRI boosts cancer detection PET/MRI ups lesion detection by 15% for some cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 16, 2021 Category: Radiology Source Type: news

IMA Clinical Research deploys AiCure's app to potential study participants, RapidSOS delivers Vitals Aware Services' data to 911 and more digital health deals
SmileDirectClub taps NexHealth's EHR API; Digital pathology companies partner on prostate cancer detection. (Source: mobihealthnews)
Source: mobihealthnews - March 15, 2021 Category: Information Technology Tags: Finance, Investing, Business Source Type: news

New MRI contrast agent enables 3D vascular mapping
South Korean researchers have developed Supramolecular Amorphous-like Iron Oxide...Read more on AuntMinnie.comRelated Reading: Nano-MRI outduels PSMA-PET/CT for prostate cancer Manganese-based MRI agent shows promise Gadolinium research should focus on skin, expert says Alternatives exist for reduced gadolinium contrast use SPION contrast could improve low-field MRI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2021 Category: Radiology Source Type: news

50,000 fewer men were urgently referred for suspected prostate cancer during pandemic
NHS England data shows the number of patients urgently referred for the cancer fell by 28 per cent between April 2020 and January of this year - about 52,000 fewer. (Source: the Mail online | Health)
Source: the Mail online | Health - March 12, 2021 Category: Consumer Health News Source Type: news

MRI-first prostate screening could reduce death rates
Performing MRI scans before biopsy on men with high prostate-specific antige...Read more on AuntMinnie.comRelated Reading: Short MRI exam shows promise for prostate cancer screening follow-up Nano-MRI outduels PSMA-PET/CT for prostate cancer MRI-targeted biopsy shows value in prostate cancer MRgFUS shows promise for prostate cancer treatment Radiation therapy takes toll on prostate cancer patients' finances (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 11, 2021 Category: Radiology Source Type: news

Targeted screening for prostate cancer could prevent one in six deaths
(University College London) A national screening programme targeted at those men who are genetically pre-disposed to prostate cancer, and involving a blood test and MRI scan before an invasive biopsy, could prevent one in six prostate cancer deaths and significantly reduce over-diagnosis, finds a new study led by UCL researchers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

Novel Radiopharmaceutical Beats Cabazitaxel in mCRPC Novel Radiopharmaceutical Beats Cabazitaxel in mCRPC
The first comparator study shows that the novel radiopharmaceutical Lu-PSMA-6170 bettered chemotherapy for metastatic castration-resistant prostate cancer (mCRPC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Sarcosine Distinguishes Prostate Cancer From BPH Sarcosine Distinguishes Prostate Cancer From BPH
This study assessed the diagnostic performance of plasma sarcosine as a complementary biomarker to PSA. How well does it distinguish malignancy from benign prostatic hyperplasia?Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Quibim's AI software for prostate MRI cleared by FDA
Quibim's qp-Prostate artificial intelligence software for analyzing prostat...Read more on AuntMinnie.comRelated Reading: Can radiology AI save itself? Top healthcare trends on display at RSNA 2020 AI, radiomics predicts prostate cancer recurrence (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 5, 2021 Category: Radiology Source Type: news

$1m grant funds research on potential new RX for prostate cancer
(Louisiana State University Health Sciences Center) The Biomedical Laboratory Research and Development Branch of the Veterans Administration (VA) has awarded Hari Koul, PhD, Professor and Interim Chairman of the Department Biochemistry& Molecular Biology at LSU Health New Orleans School of Medicine, $1,056,317 in research funding over four years to help find new treatments for prostate cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 3, 2021 Category: International Medicine & Public Health Source Type: news

Threshold ID ’ d for Urine Test to Rule Out Prostate Cancer
In validation study, 3.7 percent of grade group ≥2 cancers missed with MyProstateScore value ≤10 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 2, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Urology, Journal, Source Type: news